These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19054692)

  • 1. The use of activated factor VII for ventricular septal defect closure in a pediatric patient with hemophilia A and a high titer of inhibitor.
    de Souza DG; Waldron PE; Peeler BB; Baum VC
    J Cardiothorac Vasc Anesth; 2009 Oct; 23(5):679-81. PubMed ID: 19054692
    [No Abstract]   [Full Text] [Related]  

  • 2. [Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors].
    Kawasaki Y; Saeki N; Kawamoto M; Yuge O; Fujii T
    Masui; 2005 Aug; 54(8):926-8. PubMed ID: 16104555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision.
    Leblebisatan G; Sasmaz I; Antmen B; Kilinc Y; Sizmaz S; Yagmur M
    Haemophilia; 2006 Mar; 12(2):187-9. PubMed ID: 16476096
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.
    Chuansumrit A; Sirachainan N; Panuwannakorn M; Wongwerawattanakoon P; Kadegasem P; Choeyprasert W; Sasanakul W
    Haemophilia; 2013 May; 19(3):e182-3. PubMed ID: 23600908
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
    Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
    Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
    Majumdar G; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries.
    Young G; Escobar MA; Pipe SW; Cooper DL
    Am J Hematol; 2017 Sep; 92(9):940-945. PubMed ID: 28589615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation in a patient with mild haemophilia A and low-titres of factor VIII inhibitors treated with recombinant factor VIIa. The first Argentinean case.
    Guglielmone H; Jarchum G; Minoldo S
    Haemophilia; 2011 Mar; 17(2):317-8. PubMed ID: 21332883
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring inhibitor patients with the right assays.
    Barrowcliffe TW
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S25-30. PubMed ID: 18544420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers.
    Kaya Z; Orhan Ö; Turanlı S; Yenicesu İ; Koçak Ü; Gürsel T
    Blood Coagul Fibrinolysis; 2017 Jul; 28(5):419-422. PubMed ID: 28079537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
    Levi M; Friederich PW; van der Meer J
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors.
    Hedner U
    J Thromb Haemost; 2006 Nov; 4(11):2498-500. PubMed ID: 16907841
    [No Abstract]   [Full Text] [Related]  

  • 14. Controversies and challenges in elective orthopedic surgery in patients with hemophilia and inhibitors.
    Jiménez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Fernandez I; Hernandez-Navarro F
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S64-7. PubMed ID: 18544428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VII and haemostasis.
    Osterud B
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):175-81. PubMed ID: 2130929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction between platelets and factor VII/VIIa.
    Lau HK
    Transfus Apher Sci; 2003 Jun; 28(3):279-83. PubMed ID: 12725955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
    Carmassi F; Giannarelli C; De Giorgi A; De Negri F
    Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No protective effect of breastfeeding on inhibitor formation in severe hemophilia.
    Jansen IM; Fischer K; Van Der Bom JG; Van Den Berg HM
    Pediatr Hematol Oncol; 2005; 22(7):575-80. PubMed ID: 16166050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.